ROHTESH S MEHTA to Young Adult
This is a "connection" page, showing publications ROHTESH S MEHTA has written about Young Adult.
Connection Strength
0.755
-
Interplay between donor age and HLA-DP matching in 10/10?HLA-matched unrelated donor HCT. Blood Adv. 2024 10 22; 8(20):5438-5449.
Score: 0.064
-
Haploidentical vs HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations. Blood Adv. 2024 10 22; 8(20):5306-5314.
Score: 0.064
-
Haploidentical Versus Mismatched Unrelated Donor Hematopoietic Cell Transplantation: HLA Factors and Donor Age Considerations. Transplant Cell Ther. 2024 Sep; 30(9):909.e1-909.e11.
Score: 0.063
-
Combined effect of unrelated donor age and HLA peptide-binding motif match status on HCT outcomes. Blood Adv. 2024 05 14; 8(9):2235-2242.
Score: 0.062
-
Improved survival with younger HLA-matched unrelated donors versus older matched sibling donor HCT with PTCy-prophylaxis. Leukemia. 2024 Jun; 38(6):1432-1434.
Score: 0.062
-
Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. Bone Marrow Transplant. 2021 06; 56(6):1316-1324.
Score: 0.049
-
Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. J Clin Oncol. 2020 06 20; 38(18):2062-2076.
Score: 0.047
-
Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults. Haematologica. 2016 06; 101(6):764-72.
Score: 0.035
-
Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol. 2016 05; 173(3):444-55.
Score: 0.035
-
The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation. Clin Lymphoma Myeloma Leuk. 2014 Feb; 14(1):e1-5.
Score: 0.030
-
Decreasing chronic graft-versus-host disease rates in all populations. Blood Adv. 2024 Nov 26; 8(22):5829-5837.
Score: 0.016
-
Gastrointestinal involvement refines prognosis in minnesota standard risk acute graft-vs.-host disease. Bone Marrow Transplant. 2024 Nov; 59(11):1594-1600.
Score: 0.016
-
Returning to Work Following Hematopoietic Cell Transplantation: The Survivor's Perspective. Transplant Cell Ther. 2024 Jun; 30(6):612.e1-612.e12.
Score: 0.015
-
Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2024 May; 24(5):e196-e204.
Score: 0.015
-
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. J Hematol Oncol. 2022 01 29; 15(1):12.
Score: 0.013
-
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021 12 02; 138(22):2278-2289.
Score: 0.013
-
Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia. Transplant Cell Ther. 2021 08; 27(8):689-695.
Score: 0.013
-
Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol. 2021 08 20; 39(24):2710-2719.
Score: 0.013
-
Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol. 2021; 144(1):74-81.
Score: 0.012
-
Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. Am J Hematol. 2019 12; 94(12):1382-1387.
Score: 0.011
-
Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia. Clin Lymphoma Myeloma Leuk. 2019 09; 19(9):560-569.
Score: 0.011
-
Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol. 2018 Nov; 5(11):e532-e542.
Score: 0.011
-
Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation. Front Immunol. 2018; 9:2444.
Score: 0.011
-
Is a matched unrelated donor search needed for all allogeneic transplant candidates? Blood Adv. 2018 09 11; 2(17):2254-2261.
Score: 0.010
-
Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. Blood. 2018 06 28; 131(26):2989-2992.
Score: 0.010
-
Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Blood Adv. 2018 04 24; 2(8):909-922.
Score: 0.010
-
Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. Bone Marrow Transplant. 2018 03; 53(3):315-325.
Score: 0.010
-
KIR gene haplotype: an independent predictor of clinical outcome in MDS patients. Blood. 2016 12 15; 128(24):2819-2823.
Score: 0.009
-
IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation. Blood. 2016 09 08; 128(10):1346-61.
Score: 0.009
-
Better allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica. 2015 Oct; 100(10):1361-70.
Score: 0.008
-
Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood. 2015 May 07; 125(19):2885-92.
Score: 0.008